These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 2472582)

  • 41. On/off syndrome in Parkinson's disease and intravenous levodopa.
    Clough CG
    Lancet; 1982 Oct; 2(8301):765. PubMed ID: 6125830
    [No Abstract]   [Full Text] [Related]  

  • 42. Levodopa methyl ester treatment of Parkinson's disease.
    Juncos JL; Mouradian MM; Fabbrini G; Serrati C; Chase TN
    Neurology; 1987 Jul; 37(7):1242-5. PubMed ID: 3601092
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-induced motor complications in dopa-responsive dystonia: implications for the pathogenesis of dyskinesias and motor fluctuations.
    de la Fuente-Fernández R
    Clin Neuropharmacol; 1999; 22(4):216-9. PubMed ID: 10442251
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Early morning dystonia: a complication of levodopa therapy in Parkinson disease. Presentation of 4 cases].
    Molina Arjona JA; Arnal García C; Calandre Hoenigsfeld L; Bermejo Pareja F
    Med Clin (Barc); 1984 Jun; 83(2):47-9. PubMed ID: 6471944
    [No Abstract]   [Full Text] [Related]  

  • 45. [A case of Parkinson's disease following dystonia].
    Yasuda C; Takei T; Uozumi T; Toyota T; Yuhi T; Adachi H
    Rinsho Shinkeigaku; 2016 Sep; 56(9):600-4. PubMed ID: 27498816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic strategies to prevent motor complications in Parkinson's disease.
    Kieburtz K
    J Neurol; 2008 Aug; 255 Suppl 4():42-5. PubMed ID: 18821085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Control of on/off phenomenon by continuous intravenous infusion of levodopa.
    Quinn N; Parkes JD; Marsden CD
    Neurology; 1984 Sep; 34(9):1131-6. PubMed ID: 6540399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum vitamin B(12) and folate levels in Parkinson's disease patients treated with duodenal levodopa infusion.
    Santos-García D; Macías M; Llaneza M; Grande M; de la Fuente-Fernández R
    Mov Disord; 2011 Feb; 26(3):558-9. PubMed ID: 20960480
    [No Abstract]   [Full Text] [Related]  

  • 49. Clinical aspects of motor fluctuations in Parkinson's disease.
    Poewe WH
    Neurology; 1994 Jul; 44(7 Suppl 6):S6-9. PubMed ID: 8047260
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.
    Antonini A; Bondiolotti G; Natuzzi F; Bareggi SR
    Eur Neuropsychopharmacol; 2010 Oct; 20(10):683-7. PubMed ID: 20570113
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term treatment response and fluorodopa positron emission tomographic scanning of parkinsonism in a family with dopa-responsive dystonia.
    Nygaard TG; Takahashi H; Heiman GA; Snow BJ; Fahn S; Calne DB
    Ann Neurol; 1992 Nov; 32(5):603-8. PubMed ID: 1449240
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
    Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
    Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Motor symptoms in Parkinson disease].
    Larsen JP; Beiske AG; Bekkelund SI; Dietrichs E; Tysnes OB; Vilming ST; Aasly JO
    Tidsskr Nor Laegeforen; 2008 Sep; 128(18):2068-71. PubMed ID: 18846123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease.
    Nyholm D
    Expert Rev Neurother; 2006 Oct; 6(10):1403-11. PubMed ID: 17078781
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polyneuropathy while on duodenal levodopa infusion in Parkinson's disease patients: we must be alert.
    Santos-García D; de la Fuente-Fernández R; Valldeoriola F; Palasí A; Carrillo F; Grande M; Mir P; De Fabregues O; Casanova J
    J Neurol; 2012 Aug; 259(8):1668-72. PubMed ID: 22270132
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
    Nutt JG; Woodward WR; Hammerstad JP; Carter JH; Anderson JL
    N Engl J Med; 1984 Feb; 310(8):483-8. PubMed ID: 6694694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
    Ricciardi L; Bove F; Espay KJ; Lena F; Modugno N; Poon YY; Krikorian R; Espay AJ; Fasano A
    Mov Disord; 2016 Apr; 31(4):597-8. PubMed ID: 26946221
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of dystonia in Parkinson's disease.
    Tsui JK
    Adv Neurol; 2003; 91():361-4. PubMed ID: 12442694
    [No Abstract]   [Full Text] [Related]  

  • 59. DOPA-responsive dystonic parkinsonism--pathophysiologic considerations.
    Segawa M; Nishiyama N; Nomura Y
    Adv Neurol; 1999; 80():389-400. PubMed ID: 10410746
    [No Abstract]   [Full Text] [Related]  

  • 60. [Aggravation of Parkinson's disease after inadequate use of levodopa in controlled-release preparations].
    Mateo D; Dobato JL; Giménez-Roldán S
    Neurologia; 1995 Jan; 10(1):7-13. PubMed ID: 7893519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.